AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24607755 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labor (IOL) at 40 weeks' gestation
Number of subjects: 0
Study 24607755 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labor (IOL) at <40 weeks' gestation
Number of subjects: 0
Study 24607755 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous labor at <40 weeks' gestation
Number of subjects: 0
Study 23539236 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (14 mg tapered over 3 days)
Number of subjects: 381
Study 23539236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381
Study 23539236 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control (80-110 mg dl(‐1))
Number of subjects: 381
Study 23539236 — intervention group
Group type: COMPARATOR
Intervention: Conventional glucose control (180-200 mg dl(‐1))
Number of subjects: 381
Study 23539236 — intervention group
Group type: EXPERIMENTAL
Intervention: Lighter anaesthesia (bispectral index target of 55)
Number of subjects: 381
Study 23539236 — intervention group
Group type: COMPARATOR
Intervention: Deeper anaesthesia (bispectral index target of 35)
Number of subjects: 381
Study 20337844 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (diet and exercise)
Number of subjects: 4864
Study 20337844 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss diets (low fat, high protein, Mediterranean)
Number of subjects: 4864
Study 20337844 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise
Number of subjects: 4864
Study 17904917 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preference depression treatment
Number of subjects: 200
Study 16966541 — intervention group
Group type: EXPERIMENTAL
Intervention: Occurrence of relapses in the first 4 months on study
Number of subjects: 256
Study 16966541 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation dataset (n = 320)
Number of subjects: 256
Study 12960555 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled morphine (3 inhalations [6.6 mg])
Number of subjects: 89
Study 12960555 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine (4 mg)
Number of subjects: 89
Study 12960555 — intervention group
Group type: COMPARATOR
Intervention: Inhaled morphine (1 inhalation [2.2 mg])
Number of subjects: 89
Study 12960555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 10583449 — intervention group
Group type: EXPERIMENTAL
Intervention: Remikiren (600 mg day‐1) single dose
Number of subjects: 25
Study 10583449 — intervention group
Group type: EXPERIMENTAL
Intervention: Remikiren (600 mg day‐1) multiple doses (8 days)
Number of subjects: 25
Study 8727627 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft cervical collar
Number of subjects: 250
Study 8727627 — intervention group
Group type: COMPARATOR
Intervention: No collar (control)
Number of subjects: 250
Study 2021138 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised 1‐y walking program
Number of subjects: 36
Study 2021138 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dietary calcium (milk supplement, 831 mg/d)
Number of subjects: 36
Study 2021138 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (41 mg/d)
Number of subjects: 36
Study 2021138 — intervention group
Group type: COMPARATOR
Intervention: Sedentary women
Number of subjects: 36
Study 2021138 — intervention group
Group type: EXPERIMENTAL
Intervention: Neither exercise nor dietary calcium
Number of subjects: 36
Study 6982807 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic secretin (Hoe 0690)
Number of subjects: 71
Study 6982807 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 71
Study 29564720 — intervention group
Group type: EXPERIMENTAL
Intervention: Accordion suturing technique
Number of subjects: 30
Study 29564720 — intervention group
Group type: COMPARATOR
Intervention: Non-accordion (standard) suturing technique
Number of subjects: 30
Study 29564720 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 27317302 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 138
Study 27317302 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 138
Study 27317302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 25409911 — intervention group
Group type: EXPERIMENTAL
Intervention: Chat-based consultations
Number of subjects: 290
Study 25409911 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 290
Study 23016532 — intervention group
Group type: EXPERIMENTAL
Intervention: Skincare regimen containing retinol, adenosine, and hyaluronic acid applied for 2 months after botulinum toxin A injection
Number of subjects: 0
Study 23016532 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 23016532 — intervention group
Group type: EXPERIMENTAL
Intervention: Skincare regimen
Number of subjects: 0
Study 19909752 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a 180 microg/wk plus ribavirin 1000/1200 mg/day for 48 weeks (group A)
Number of subjects: 551
Study 19909752 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a 180 microg/wk plus ribavirin 1000/1200 mg/day for 72 weeks (group B)
Number of subjects: 551
Study 17651539 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg
Number of subjects: 4741
Study 17651539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4741
Study 16088179 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) prior to Pringle maneuver
Number of subjects: 75
Study 16088179 — intervention group
Group type: COMPARATOR
Intervention: Pringle maneuver
Number of subjects: 75
Study 16088179 — intervention group
Group type: COMPARATOR
Intervention: Surgery without vascular clamping
Number of subjects: 75
Study 12042561 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 20 mg/kg/d
Number of subjects: 43
Study 12042561 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 30 mg/kg/d
Number of subjects: 43
Study 12042561 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin 50 mg/kg/d
Number of subjects: 43
Study 9462389 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop ileostomy
Number of subjects: 76
Study 9462389 — intervention group
Group type: COMPARATOR
Intervention: Loop transverse colostomy
Number of subjects: 76
Study 7630132 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 17
Study 7630132 — intervention group
Group type: COMPARATOR
Intervention: Defined formula enteral diet (ENT)
Number of subjects: 17
Study 2744311 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD/DVI pacing
Number of subjects: 60
Study 2744311 — intervention group
Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 60
Study 2744311 — intervention group
Group type: COMPARATOR
Intervention: VVI mode
Number of subjects: 60
Study 2744311 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD/DVI mode
Number of subjects: 60
Study 1234631 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole abdominal irradiation with additional irradiation to the pelvis
Number of subjects: 149
Study 1234631 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with melphalan
Number of subjects: 149
Study 1234631 — intervention group
Group type: COMPARATOR
Intervention: Whole abdominal irradiation
Number of subjects: 149
Study 30570431 — intervention group
Group type: EXPERIMENTAL
Intervention: GalNAc3-conjugated PS-modified 2'-O-methoxyethyl ASOs
Number of subjects: 0
Study 27277839 — intervention group
Group type: EXPERIMENTAL
Intervention: B-clade Tat immunization (30 μg, intradermally, three times at 4-week intervals)
Number of subjects: 200
Study 27277839 — intervention group
Group type: EXPERIMENTAL
Intervention: B-clade Tat immunization
Number of subjects: 200
Study 25087673 — intervention group
Group type: COMPARATOR
Intervention: Continuous androgen deprivation
Number of subjects: 1535
Study 25087673 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent androgen deprivation
Number of subjects: 1535
Study 22872346 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational actions on oral health (school and home visits)
Number of subjects: 80
Study 22872346 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational actions on oral health (school group)
Number of subjects: 80
Study 20169425 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan and prednisone (standard of care)
Number of subjects: 0
Study 20169425 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide, lenalidomide, and bortezomib (new therapies)
Number of subjects: 0
Study 18946688 — intervention group
Group type: EXPERIMENTAL
Intervention: ADCON-L (bioresorbable carbohydrate polymer gel)
Number of subjects: 119
Study 18946688 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ADCON-L)
Number of subjects: 119
Study 18946688 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ADCON-L and Control)
Number of subjects: 119
Study 15567452 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin, 250 units/kg (n=15)
Number of subjects: 61
Study 15567452 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin, 1 mg/kg (n=16)
Number of subjects: 61
Study 15567452 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin, 200 units/kg (n=15)
Number of subjects: 61
Study 15567452 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin, 175 units/kg (n=15)
Number of subjects: 61
Study 12812387 — intervention group
Group type: EXPERIMENTAL
Intervention: Vital signs measured every 6 hours
Number of subjects: 149
Study 12812387 — intervention group
Group type: COMPARATOR
Intervention: Vital signs measured every 8 hours
Number of subjects: 149
Study 9524046 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (transdermal patch 2.5 mg/week)
Number of subjects: 20
Study 1365486 — intervention group
Group type: EXPERIMENTAL
Intervention: Droxicam
Number of subjects: 20
Study 1365486 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam
Number of subjects: 20
Study 6351669 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg glucose-free bupivacaine (0.5% or 0.75%)
Number of subjects: 60
Study 6351669 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg glucose-free bupivacaine (0.5% or 0.75%)
Number of subjects: 60
Study 6351669 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg glucose-free bupivacaine (0.5% or 0.75%)
Number of subjects: 60
Study 6351669 — intervention group
Group type: EXPERIMENTAL
Intervention: Various volumes and concentrations of bupivacaine
Number of subjects: 60
Study 6351669 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (various doses)
Number of subjects: 60
Study 31815260 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose L. casei (1 bottle per day, n = 142)
Number of subjects: 429
Study 31815260 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose L. casei (2 bottles per day, n = 143)
Number of subjects: 429
Study 31815260 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention, n = 144)
Number of subjects: 429
Study 31815260 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose L. casei
Number of subjects: 429
Study 31815260 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose L. casei
Number of subjects: 429
Study 31815260 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 429
Study 30825384 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic amoxicillin 500 mg/metronidazole 400 mg (3×/day, 7 days, n = 170)
Number of subjects: 345
Study 30825384 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 175)
Number of subjects: 345
Study 29476990 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral TXA (3 doses of 2 g oral TXA postoperatively)
Number of subjects: 108
Study 29476990 — intervention group
Group type: COMPARATOR
Intervention: Intravenous TXA (3 doses of 1 g intravenous TXA postoperatively)
Number of subjects: 108
Study 27139422 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (1.16 g DHA/day for 8 weeks)
Number of subjects: 15
Study 27139422 — intervention group
Group type: COMPARATOR
Intervention: Placebo (non-enriched beverage)
Number of subjects: 15
Study 27139422 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 15
Study 27139422 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature (39.5 °C)
Number of subjects: 15
Study 25179968 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate II or HeartWare LVAD
Number of subjects: 126
Study 22094353 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (AT, n=17)
Number of subjects: 87
Study 22094353 — intervention group
Group type: COMPARATOR
Intervention: Hormone therapy (HT, n=34)
Number of subjects: 87
Study 22094353 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy plus atorvastatin (HT+AT, n=36)
Number of subjects: 87
Study 21290833 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 60
Study 21290833 — intervention group
Group type: COMPARATOR
Intervention: Medication (Diclofenac Sodium)
Number of subjects: 60
Study 17704022 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/d gamma-tocopherol
Number of subjects: 39
Study 17704022 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/d gamma-tocopherol
Number of subjects: 39
Study 17704022 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 39
Study 15568206 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (2 mg/kg)
Number of subjects: 68
Study 15568206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 11837380 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg ASA (oral)
Number of subjects: 13
Study 11837380 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg D,L‐lysine‐mono‐acetylsalicylate (Lys‐ASA) (oral and intravenous)
Number of subjects: 13
Study 11837380 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg Lys‐ASA (oral)
Number of subjects: 13
Study 9428456 — intervention group
Group type: EXPERIMENTAL
Intervention: Total-dose intravenous iron dextran infusion
Number of subjects: 43
Study 9428456 — intervention group
Group type: COMPARATOR
Intervention: 500-mg infusion to total dose
Number of subjects: 43
Study 9428456 — intervention group
Group type: COMPARATOR
Intervention: 100-mg bolus to total dose
Number of subjects: 43
Study 8562292 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 1000 mg
Number of subjects: 0
Study 8562292 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg
Number of subjects: 0
Study 8562292 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 60 mg
Number of subjects: 0
Study 8562292 — intervention group
Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 0
Study 2200632 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopromide (50 or 100 ml, 370 mgI/ml)
Number of subjects: 0
Study 2200632 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol (50 or 100 ml, 370 mgI/ml)
Number of subjects: 0
Study 7387335 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg beta-endorphin intravenous injection
Number of subjects: 9
Study 7387335 — intervention group
Group type: COMPARATOR
Intervention: 10 mg morphine sulfate
Number of subjects: 9
Study 30946445 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Number of subjects: 0
Study 30946445 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 0
Study 27810904 — intervention group
Group type: EXPERIMENTAL
Intervention: Motolimod (VTX-2337) at 3.0 mg/m2 combined with cetuximab
Number of subjects: 13
Study 27810904 — intervention group
Group type: EXPERIMENTAL
Intervention: Motolimod (VTX-2337) at 3.5 mg/m2 combined with cetuximab
Number of subjects: 13
Study 27810904 — intervention group
Group type: EXPERIMENTAL
Intervention: Motolimod (VTX-2337)
Number of subjects: 13
Study 26982794 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol 0.05%
Number of subjects: 40
Study 26982794 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (petrolatum or lacquer)
Number of subjects: 40
Study 24114437 — intervention group
Group type: EXPERIMENTAL
Intervention: Precision training (stepping over obstacles and onto targets on the ground)
Number of subjects: 0
Study 24114437 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (treadmill training with body weight support, if needed)
Number of subjects: 0
Study 24114437 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-Meter Walk Test (10MWT)
Number of subjects: 0
Study 24114437 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-Minute Walk Test (6MWT)
Number of subjects: 0
Study 24114437 — intervention group
Group type: EXPERIMENTAL
Intervention: SCI-FAP
Number of subjects: 0
Study 25191546 — intervention group
Group type: EXPERIMENTAL
Intervention: High ALA and sn-1,3-DAG
Number of subjects: 23
Study 25191546 — intervention group
Group type: COMPARATOR
Intervention: High ALA and TAG
Number of subjects: 23
Study 19875397 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental pulmonary vein isolation (S‐PVI)
Number of subjects: 101
Study 19875397 — intervention group
Group type: COMPARATOR
Intervention: Circumferential pulmonary vein isolation (C‐PVI)
Number of subjects: 101
Study 17264187 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (10 mg)
Number of subjects: 24
Study 17264187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 14572304 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation
Number of subjects: 47
Study 14572304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 14572304 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue medication (oxygen, dexamethasone, acetazolamide)
Number of subjects: 47
Study 11269488 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS) plus medical therapy
Number of subjects: 0
Study 11269488 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 0
Study 9680346 — intervention group
Group type: EXPERIMENTAL
Intervention: MACOP-B (methotrexate with leucovorin, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin)
Number of subjects: 40
Study 9680346 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine)
Number of subjects: 40
Study 8044606 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Number of subjects: 44
Study 8044606 — intervention group
Group type: COMPARATOR
Intervention: Adrenaline injection (1:10,000)
Number of subjects: 44
Study 2141488 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethyl stilboestrol (DES) 3 mg/day
Number of subjects: 250
Study 2141488 — intervention group
Group type: COMPARATOR
Intervention: Goserelin 3.6 mg/month
Number of subjects: 250
Study 271171 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous treatment (CAT)
Number of subjects: 101
Study 271171 — intervention group
Group type: COMPARATOR
Intervention: Mild induction program (VAMP)
Number of subjects: 101
Study 31850687 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance capecitabine + bevacizumab (CAP-B)
Number of subjects: 450
Study 31850687 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 450
Study 31492102 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human thrombopoietin (rhTPO)
Number of subjects: 200
Study 31492102 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment based on Surviving Sepsis Campaign guidelines)
Number of subjects: 200
Study 27649469 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictures of natural vulvas
Number of subjects: 43
Study 27649469 — intervention group
Group type: COMPARATOR
Intervention: Pictures of neutral objects
Number of subjects: 43
Study 26278623 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based CBT
Number of subjects: 397
Study 26278623 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 397
Study 23925361 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg every 4 weeks
Number of subjects: 208
Study 23925361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 21324133 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly Administered Antiretroviral Therapy (DAART) for 12 months
Number of subjects: 107
Study 21324133 — intervention group
Group type: COMPARATOR
Intervention: Self-Administered Therapy (SAT)
Number of subjects: 107
Study 19359420 — intervention group
Group type: EXPERIMENTAL
Intervention: SCI patients
Number of subjects: 12
Study 19359420 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 12
Study 17061611 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (2000 mg per day for 20 days)
Number of subjects: 414
Study 17061611 — intervention group
Group type: COMPARATOR
Intervention: Baseline serum calcium and alkaline phosphatase levels
Number of subjects: 414
Study 14734700 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction group (102 smokers)
Number of subjects: 153
Study 14734700 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group (49 smokers)
Number of subjects: 153
Study 11553186 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 16
Study 11553186 — intervention group
Group type: COMPARATOR
Intervention: Soluble human insulin
Number of subjects: 16
Study 9713447 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 1600 micrograms per day
Number of subjects: 79
Study 9713447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 7871359 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultivation
Number of subjects: 20
Study 7871359 — intervention group
Group type: EXPERIMENTAL
Intervention: Evalusite (ELISA kit)
Number of subjects: 20
Study 7871359 — intervention group
Group type: EXPERIMENTAL
Intervention: OmniGene (DNA probes)
Number of subjects: 20
Study 7871359 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect immunofluorescence (IIF)
Number of subjects: 20
Study 7871359 — intervention group
Group type: COMPARATOR
Intervention: Commercial systems
Number of subjects: 20
Study 2493897 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (two 25 mg doses in 24 hours)
Number of subjects: 64